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Objectives, We analysed our results with the use of aortic polytetrafluoroethylene (PTFE) grafts over the last 7.5 years. 
A historical comparison was also made between the results with non-stretch PTFE (NS-PTFE) (1987-91) and stretch 
PTFE (S-PTFE) grafts (1991-94). 
Materials: 244 infrarenal aortic replacements or bypasses with PTFE grafts were performed at the University of Iowa 
Hospitals and Clinics from January 1987 to June 1994. Infrarenal aortic replacement was indicated for aortic aneurysmal 
disease in 192 patients (elective 151, symptomatic 20, ruptured 21) and bypass for aorto-iliac occlusive disease in 52 
patients (disabling claudication 28, limb salvage 24). Patients ranged in age from 37 to 93 years (mean 68 years). There 
were 161 males and 83 females. Medical risk factors included hypertension (55%), coronary artery disease (31%), COPD 
(23%), diabetes mellitus (12%), chronic renal failure (9%), and smoking (61%). Aortic replacement or bypass was done 
with a NS-PTFE graft in 108 patients (44%) and a S-PTFE graft in 136 patients (56%). Postoperative ultrasound (US) 
scans and~or CT-studies were available in 40 patients with NS-PTFE and 26 patients with S-PTFE grafts. 
Main results: The 30 day operative mortality was: elective AAA patients (1.3%), symptomatic AAA patients (10%), 
ruptured AA_A patients (48%), limb salvage patients (4.1%) and disabling claudication patients (0%). Graft related 
complications included five graft limb thromboses (4 NS-PTFE, 1 S-PTFE). Two thromboses occurred perioperatively and 
the three others at 24, 28 and 30 months postoperatively. Two other graft related complications included a mixed 
pseudomonas and streptococcus groin infection with a culture negative perigraft fluid collection occurring 3 weeks 
following surgery (NS-PTFE), and distal aortic anastomotic suture line bleed on the first postoperative day following 
replacement ofa ruptured AAA with a S-PTFE graft. Based on US and~or CT imaging studies, the mean internal diameters 
of the bodies of 40 NS-PTFE and 26 S-PTFE grafts were 11% and 10% greater than the manufacturer's specified sizes at 
a mean follow-up duration of 36 and 10 months respectively. 
Conclusions" These data reveal that a PTFE graft performs atisfactorily in the aortic position with minimal adverse 
clinical sequelae over a 7.5 year period. Continued long term follow up data will determine the ultimate suitability of aortic 
PTFE grafts. 
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Introduction 
Polytetrafluoroethylene grafts were first introduced in 
the 1970s for clinical usage for infrainguinal bypass 
grafting. Larger diameter PTFE grafts were subse- 
quently developed and utilised clinically for aortic 
replacement or bypass beginning in 1980. The initial 
prototypes were thick and stiff resulting in poor 
handling characteristics. Several evolutions in graft 
design have resulted in graft improvements resulting 
in the currently available stretch aortic PTFE graft 
introduced clinically in April 1991. Although PTFE has 
been increasingly utilised as an aortic prosthesis, there 
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are few reports of long term results. 1-s Hence, we 
reviewed 7.5 years experience with the use of aortic 
PTFE grafts to evaluate their performance and review 
the incidence of graft related complications. 
Patients and Methods 
The medical records of all patients who underwent an 
infrarenal aortic replacement or bypass with a PTFE 
graft for either aneurysmal or atherosclerotic o clusive 
disease were reviewed. Patients who had undergone a 
suprarenal aortic procedure and patients who had an 
infrarenal aortic replacement with a Dacron graft were 
excluded from this analysis. Patient demographics, 
indications for surger3~ associated medical risk factors, 
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surgical complications and subsequent follow-up data 
were gathered from the medical records. Operative 
details such as the surgical approach, type of PTFE 
graft (non-stretch or stretch), configuration of the graft 
(tube or bifurcated), size of the graft, site of distal 
anastomoses, and concomitant surgical procedures 
were noted. Intraoperative and postoperative graft 
related and other complications were also recorded. 
Patients were usually seen in the vascular surgery 
clinic 1 month after discharge and then annually 
thereafter if the procedure was uncomplicated. In 
addition to a clinical evaluation, ankle-arm indices 
(AAIs) were obtained uring each follow up examina- 
tion. Selected patients underwent an aortic ultrasound 
(US) or CT-study to evaluate either graft healing, 
further aneurysmal disease or for work up of post- 
operative abdominal pain. 
The clinical experience with NS-PTFE grafts and 
S-PTFE grafts was compared in this study. The age of 
the patients, duration of follow up and the graft body 
diameters as determined by US and/or CT-imaging 
studies between the two groups were compared for 
statistical significance using a t-test. Other patient 
variables uch as associated medical conditions, indi- 
cations for surger~ initial size and configuration of the 
PTFE grafts were analysed by Chi-square test. Com- 
plications related to the PTFE grafts were also ana- 
lysed by using Chi-square test. A p < 0.05 was con- 
sidered significant. 
The cumulative primary patencies of the grafts were 
calculated by life table analysis as per the recom- 
mendations of the SVS/ISCVS ad hoc committee on 
reporting standards. 6 Survival rates were also calcu- 
lated using life table analysis. Patency and survival 
rates with a standard error less than 10% were 
reported. 
Results 
Between January 1987 and June 1994, 244 patients 
with a mean age of 68 years (range 37-93 years) were 
operated upon for infrarenal abdominal aortic aneu- 
rysm (AAA) or atherosclerotic aortoiliac occlusive 
disease (AIOD) with implantation of either a non- 
stretch or a stretch (PTFE) graft (W.L. Gore and 
Associates, Inc., Flagstaff, AZ 86002, U.S.A.). The age 
of the patients with NS-PTFE grafts was 68 + 9 years 
and was comparable to the age of patients with 
S-PTFE grafts (68 + 11 years). 
Non-stretch PTFE (NS-PTFE) grafts were used in 
108 patients until April 1991. Since then stretch PTFE 
(S-PTFE) grafts were used in preference over other 
Table 1. Size of the different PTFE grafts implanted 
Size (n) Non-stretch Stretch 
PTFE (108) PTFE (136) 
Tube Grafts (119) 
14 mm (1) 1 0 
16 mm (31) 12 19 
18 mm (68) 37 31 
20 mm (19) 3 16 
Bifurcated Grafts (125) 
14 x 7 mm (21) 14 7 
16 x 8 mm (43) 13 30 
18 x 9 mm (33) 13 20 
20 x 10 mm (28) 15 13 
types of aortic grafts in 136 patients. In the NS-PTFE 
group, there were 53 (49%) tube grafts and 55 (51%) 
bifurcated grafts. Similarly, there were 66 tube grafts 
(49%) and 70 bifurcated grafts (51%) in the S-PTFE 
group. The sizes of the NS-PTFE and the S-PTFE grafts 
used are shown in Table 1. In patients who received a
NS-PTFE bifurcated graft, the distal anastomoses were 
to both iliac arteries (28), both femoral arteries (22) or 
an iliac artery on one side and femoral artery on the 
other (5). In the S-PTFE group, the distal anastomoses 
of the bifurcated grafts were to both iliac arteries (27), 
both femoral arteries (40) or a combination (3). 
There were 71 males and 37 females in the NS-PTFE 
group, and 90 males and 46 females in the S-PTFE 
group. The associated medical conditions among these 
244 patients are listed in Table 2. Aortic replacement 
for an abdominal aortic aneurysm (AAA) was per- 
formed in 192 patients (79%) and a bypass for 
aortoiliac occlusive disease (AIOD) in 52 patients 
(21%). The various indications for surgery are 
depicted in Table 3. There was no significant difference 
between the two groups with regard to the indications 
for surgery. The surgical approach and choice of graft 
material for aortic replacement was the individual 
surgeon's preference. Combined aortic procedures 
were performed in 39 patients. These additional 
procedures included renal artery revascularisation (17 
S-PTFE, 16 NS-PTFE), hepatic artery revascularisation 
(1 S-PTFE, 1 NS-PTFE), celiac artery revascularisation 
(1 S-PTFE), and superior mesenteric artery revascular- 
isation (2 S-PTFE, 1NS-PTFE). Other combined 
procedures included cholecystectomy (2 S-PTFE, 3 
Table 2. Medical risk factors 
Medical condition NS-PTFE S-PTFE 
Hypertension 58 (54%) 76 (56%) 
Coronary artery disease 37 (34%) 39 (29%) 
COPD 33 (31%) 22 (16%) 
Diabetes mellitus 16 (15%) 14 (10%) 
Chronic renal failure 
(serum creatinine >2.0 mg/dl) 11 (10%) 10 (7%) 
Smoking 69 (64%) 80 (59%) 
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Table 3. Indications for aortic replacement or bypass 
Indications for surgery NS-PTFE S-PTFE 
Aneurysmal disease (79%)* 
Elective (79 %) 72 79 
Symptomatic (10%) 11 9 
Ruptured (11%) 5 16 
Aortoiliac occlusive disease (21%)* 
Disabling claudication (54%) 10 18 
Limb salvage (46%) 10 14 
"No significant difference between the two groups with regard tc 
indications for surgery, aneurysmal disease or aortoiliac occlusiw 
disease by Chi square test, p=0.43. 
NS-PTFE), repair of aortocaval fistula (1 NS-PTFE), 
repair of aortorenal vein fistula (1 S-PTFE), repair of 
femoral arteriovenous fi tula (1 S-PTFE) and miscella- 
neous (3 S-PTFE, 4 NS-PTFE). 
Patients with NS-PTFE grafts were followed up for 
a mean duration of 40 months (range 0-87 months), 
which was significantly longer than the follow-up of 
the S-PTFE aortic grafts who had a mean duration of 
follow up of 14 months (range 0-40 months). Seven 
patients with NS-PTFE grafts (6%) and six patients 
with S-PTFE grafts (4%) were lost to follow-up beyond 
3 months after their aortic surgery. Excepting the 
longer duration of follow-up of the NS-PTFE grafts, all 
the other variables between the two groups were not 
significantly different (p > 0.05). 
Forty patients with a NS-PTFE graft had at least one 
US and/or CT scan to evaluate ither the aortic graft, 
further aortic aneurysmal disease or unexplained 
abdominal pain during follow-up. Among these 40 
patients, 30 had an US scan alone, seven had a CT 
study alone and three had both. Similarly 26 patients 
with a S-PTFE graft underwent either an US scan and/ 
or a CT study. Of these 26 patients, 18 had an US scan 
alone, six had a CT study alone, and two had both. 
Five patients with NS-PTFE grafts and two patients 
with S-PTFE grafts had two or more US studies during 
their follow-up. Based on these imaging studies, the 
mean internal diameter of the bodies of the NS-PTFE 
grafts was 11% greater than the manufacturer's 
specified size. The measured internal diameter of the 
bodies of the S-PTFE grafts was 10% greater than the 
specified size. These calculations were based on 
measuring the internal diameter of the bodies of the 
grafts on the imaging studies and these patients who 
had the ultrasound and/or CT scans had been 
followed up to a mean duration of 36 months and 10 
months respectively. Moreover, in the seven patients 
who had two or more of these imaging studies done, 
we did not detect any progressive dilatation of the NS- 
PTFE and S-PTFE grafts. 
Major non-fatal complications (excluding graft 
related) occurring during the 30-day peri-operative 
period are listed in Table 4. Complications resulting in 
death occurred in 15 patients and the causes are listed 
in Table 5. The 30-day elective operative mortality for 
the entire series was 1.5%. On further analysis with 
respect o the different indications for surger3¢ the 
30-day operative mortality was found to be: elective 
AAA patients (1.3%), symptomatic AAA patients 
(10%), ruptured AAA patients (48%), limb salvage 
patients (4.1%), and disabling claudication patients 
(0%). Of the 15 patients who died within the 30-day 
Table 4. Major non-fatal complications following aortic replace. 
ment (within 30 days) 
NS-PTFE S-PTFE 
Pulmonary complications (5) 3 
Gastrointestinal complications (5) 3 
Acute myocardial infarction (6) 2 
Acute renal failure (3) 1 
Re-operation for bleeding (2) 1 
Wound complications (5) 3 








Table 5. Causes of 30-day operative mortality 
Indication Patient Graft size* Cause of death Time interval 
Ruptured AAA: KO 18 Coagulopathy/hypothermia / ac dosis Intraop. 
CR 18 Acute myocardial infarction Intraop. 
MC 18 x 9 Acute myocardial infarction i day 
DW 16 x 8S Coagulopathy/hypothermia/acidosis i day 
WC 18S Acute myocardial infarction i day 
JS 16S Coagulopathy / hypothermia / cidosis 1 day 
HD 20S Coagulopathy / hypothermia/acidosis 1 day 
GM 18 x 9S Respiratory failure 4 day 
JB 20S Multisystem organ failure 11 day 
BS 18S ARDS 16 day 
Symptomatic AAA: MH 20 x 10 Multisystem organ failure 22 day 
WM 18 x 9 Upper GI bleeding 26 day 
Elective AAA: TM 16S Coagulopathy/hypothermia / ac dosis Intraop. 
BS 16 x 8 Hepatorenal syndrome 9 day 
Limb salvage JP 16 x 8 Renal failure 14 day 
*S = Stretch PTFE grafts. 
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perioperative period, three died intraoperatively, five 
died within 24 h of surgery and the remaining seven 
died 1-30 days following the surgical procedure. 
Twenty-one patients with a NS-PTFE graft and 14 
patients with a S-PTFE graft have expired during the 
follow-up period beyond 1 month after surgery. The 
survival rate for all the patients with PTFE grafts was 
57% at 6 years (life table analysis, S.E. < 0.1). 
Graft related complications requiring a surgical 
revision occurred in seven patients (2.9%). These 
included five graft limb thromboses, a perigraft fluid 
collection, and a distal aortic suture line bleed. The 
cumulative primary patency rate for all PTFE grafts 
was 96% at 6 years (life table analysis, S.E. < 0.1). 
There was one case of bleeding from a distal 
anastomotic suture line requiring reoperation in a 
patient who developed severe coagulopathy following 
emergency aortic replacement with a stretch PTFE 
tube graft with for a ruptured AAA. The patient died 
10 days later from multi-system organ failure. 
One patient with AIOD underwent an aortobife- 
moral bypass for limb salvage, using a non-stretch 
PTFE graft and 3 weeks later developed purulent 
drainage in both groins from which a mixed culture of 
pseudomonas and streptococcus organisms was 
obtained. A CT-scan revealed the presence of fluid 
anterior to both the distal anastomoses of the aortobi- 
femoral bypass. This patient underwent bilateral groin 
explorations, drainage of the perigraft fluid collections 
and sartorius muscle flap coverages of the distal parts 
of both the limbs of the bypass. She was given i.v. 
antibiotics for 6 weeks and remains well without 
further problems 48 months later. There were five 
other patients with significant wound complications. 
Three had a wound infection followed by superficial 
breakdown of a groin incision. The wounds were 
managed by local wound care and subsequently 
healed well without any evidence of underlying raft 
involvement. Two patients with an aorto-bifemoral 
graft (one NS-PTFE and one S-PTFE) developed a
significant lymph leak from a groin incision. These 
were managed non-operatively with local wound care 
and subsequently healed without further problems. To 
date there has been no instance of either a pseudo- 
aneurysm or a graft infection identified in this 
series. 
Discussion 
The modem era of aortic grafting began in 1948 with 
the successful implantation of an aortic homograft by 
Gross et al. for surgical correction of a coarctation of 
the thoracic aorta. 7In 1951, Oudot successfully resec- 
ted an aortic bifurcation and replaced it with an aortic 
homograft. 8 The following year Voorhees et al. 
reported the : uccessful use of tubes constructed from 
Vinyon "N" cloth in bridging arterial defects in animal 
experiments. 9 Since then a variety of materials have 
been used for aortic replacement such as Orlon, Teflon 
and Nylon. 1°-12 Since the introduction of Dacron 
aortic grafts in 1957, most surgeons have preferentially 
implanted a variety of improved Dacron bypass grafts 
as they have evolved.~3"14 Large diameter aortic PTFE 
grafts first became clinically available as an alternative 
to Dacron grafts in 1980. Early reports with the use of 
aortic PTFE grafts were encouraging. 1'2The incidence 
of graft related complications was low, but the graft 
was not very user friendly as it was significantly thick 
and relatively rigid. Over a period of years, several 
modifications in graft design resulted in the currently 
available version of the aortic stretch PTFE graft. The 
thinner and longitudinal, stretchable PTFE graft has 
improved handling characteristics making the graft 
more conforming and resistant to buckling compared 
to the earlier prototypes of this graft. Further refine- 
ments have resulted in a PTFE graft with even thinner 
limbs. This latest modification of the aortic S-PTFE 
graft was not used in this series. 
Prospective randomised trials comparing Dacron 
and PTFE grafts in the aortic position have not 
revealed any significant differences between the two 
types of grafts in terms of patency, blood loss, 
operative time, mortality and morbidity. 15'16 The 
patency rates of modern Dacron and PTFE aortic 
bifurcation grafts appear to be quite comparable with 
4 year primary patencies reported to be between 
3.15 17 90-98%." " Other criteria of clinical significance 
pertaining to the selection of an aortic prosthesis 
include graft infection, dilatation, rupture, pseudo- 
aneurysm formation, and the development of anasto- 
motic neointimal hyperplasia. 
A unique feature of the early bifurcated aortic PTFE 
graft was the transition geometry from the body of the 
graft to the graft limbs using a narrow, sharp densified 
PTFE flow-splitter, in order to closely mimick the 
haemodynamics of the normal aortic bifurcation. 
However, the stiffness of the graft at the bifurcation 
occasionally resulted in kinking or buckling of the 
origin of one graft limb unless the body of the graft 
was cut verY2short and the proximal anastomosis was 
placed high. The stretch PTFE graft technology is a 
radical transition from the prior grafts. We have not 
encountered any incidence of kinking or buckling 
with the use of the stretch aortic PTFE graft. 
The question of dilatation of Dacron grafts has been 
an important concern over the years. Some knitted 
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Dacron grafts were reported to increase more than 
20% in diameter after implantationJ 8"19 A defective 
fabrication rather than a deterioration of the Dacron 
fibre may have been responsible for some of these 
dilatations, and dilatation of grafts may in turn be 
related to development of anastomotic pseudo-aneu- 
rysmsJ 9 Also in vitro studies show that healing at 
PTFE-arterial anastomoses results in a stronger bond 
than that achieved with Dacron grafts. 2° McCroskey et 
al. reported no incidence of graft dilatation or anasto- 
motic false aneurysm in 50 consecutive aortoiliac 
reconstructions with PTFE grafts. 21 These grafts were 
however only followed for up to 18 months and it 
remains to be seen whether graft dilatation and/or 
pseudoaneurysms will occur with a longer follow up. 
The minimal dilatation of PTFE grafts may be one 
factor responsible for the absence of anastomotic 
pseudo-aneurysms reported with PTFE grafts. In our 
current study, we also did not encounter any pseudo- 
aneurysms during follow-up to date. Similarly, in a 
previous report by the senior author, a 7 year 
experience with 241 patients with aortic PTFE grafts 
revealed no incidence of dilatation, or anastomotic 
pseudoaneurysm. 5 In a report from France, CT-scan 
evaluation was performed in the early (mean 19 days) 
and late (mean 19 months) postoperative period 
following implantation of both woven and knitted 
Dacron grafts in the aortic position in order to 
evaluate for graft dilatation. 22 They found that 'the 
body of woven and knitted Dacron grafts increased in 
diameter by 13% and 28% respectively compared to 
the manufacturer's specified iameter of the graft. The 
diameter increase progressed by 2% for woven grafts 
and 6% for knitted grafts as demonstrated by late CT- 
scans. Erdoes et al. recently reported their experience 
using prospective CT-scans to evaluate 64 stretch 
PTFE grafts and compared these studies with those of 
a cohort of concurrently placed regular knitted (70%) 
as well as woven (30%) Dacron graftsJ 3 They found 
that dilatation of both the body and limbs of all the 
Dacron grafts studied was significantly higher than 
for PTFE grafts (33% vs 16.5% in the bod3~ 62% vs. 
19.3% in the limbs) compared to manufacturers' 
designated size. It is surprising to see the degree of 
dilatation reported for both knitted and woven 
Dacron grafts.22'23 The manufacturers of the grafts 
were not specified in these reports. Moreover, it is not 
known from this report by Erdoes et al. whether all of 
these grafts were followed-up with serial CT-scanning 
to evaluate them for evidence of progressive dilata- 
tion. In our current study, aortic ultrasound and/or 
CT examinations were only performed in selected 
patients. The internal diameters of the bodies of the 
grafts were measured from these studies. Based on the 
presumption that the size marked by the manu- 
facturer on the package is correct, NS-PTFE and 
S-PTFE aortic grafts had a minor degree of dilatation 
following implantation. 
Infection of an aortic prosthesis remains a matter of 
major concern. In a comparative study of 142 knitted 
Dacron and 170 PTFE aortic grafts, Cintora et al. found 
a 4% incidence of graft infection in the Dacron grafts. 3
In their series there were no aortic PTFE graft 
infections. In a 6 year prospective randomised trial 
comparing Dacron and PTFE grafts, Polterauer et al. 
found a 1.8% incidence of aortic graft infection with 
the use of PTFE grafts and none with Dacron grafts. 17 
With time we anticipate that further cases of aortic 
PTFE graft infection will be identified as the usage of 
this graft increases. Several reports indicate that PTFE 
grafts are relatively resistant to infection compared to 
Dacron grafts. 24-26 Schmitt et al. demonstrated in their 
experimental work that bacteria have a 300 times 
greater adherence to Dacron compared to PTFE. 27 In 
situ replacement with a PTFE graft has been success- 
fully reported by several authors especially for staph- 
ylococcal epidermidis Dacron aortic graft infections. 
Bandyk et al. and Miller reported good results with 
removal of the infected Dacron graft and an in situ 
replacement with a PTFE graft without evidence of 
recurrence of infection during a mean follow up 
period of 21 and 40 months respectively. 28"29 In our 
series, we did not identify an aortic PTFE graft 
infection. 
The results of this study suggest hat aortic PTFE 
grafts appear to function satisfactorily with excellent 
patency, a low infection rate, no anastomotic pseudoa- 
neurysm formation and no evidence of significant 
graft dilatation. In addition, the advent of the stretch 
PTFE aortic graft has markedly improved the graft's 
handling characteristics and conformability. Based on 
the results of this stud)~ the stretch PTFE graft is our 
current graft of choice for aortic replacement. Further 
long term follow up is needed to more fully evaluate 
this aortic graft. 
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